摘要
探讨利拉鲁肽（liraglutide）对低脂联素血症载脂蛋白E基因敲除（ApoE^-/-）小鼠糖脂代谢和成纤维细胞生长因子21（FGF-21）及其受体（FGFR）的影响。低脂联素血症加重了ApoE^-/-小鼠糖脂代谢紊乱和胰岛素抵抗，并导致了肝脏和脂肪组织FGF-21 mRNA和蛋白表达及血浆FGF-21水平明显升高，脂肪组织FGFR1和β-klotho表达降低，肝脏FGFR1-3和β-klotho均降低。利拉鲁肽干预在改善小鼠糖脂代谢紊乱和胰岛素敏感性的同时部分逆转了FGF-21及其受体的改变。
The effects of liraglutide on glucose and lipid metabolism, fibroblast growth factor-21 （ FGF-21 ） and its receptors （FGFR） in ApoE^-/- mice with hypoadiponectinemia were investigated. Hypoadiponeetinemia facilitated disturbance in glucose and lipid metabolism and insulin resistance. Compared with the control mice, FGF- 21 mRNA and protein expressions of liver and adipose tissues as well as plasma FGF-21 level were significantly increased in ApoE^-/- mice with hypoadiponeetinemia, along with lowered expressions of FGFR1 and β-klotho mRNA in adipose tissues, and expressions of FGFR1-3 and β-klotho mRNA in liver. Liraglutide administration improved glucose and lipid metabolism and insulin resistance, and partially reversed the changes of FGF-21 and its receptors induced by hypoadiponectinemia.
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2011年第9期775-777,共3页
Chinese Journal of Endocrinology and Metabolism
基金
国家自然科学基金项目（30771037、30871199、30971388、81070640）
